Many of the challenges in the field of small molecule custom synthesis are present also in the field of biologics.

Novel therapies that combine both are opening new avenues of therapy but also new challenges to overcome. Exeris introduces new capability and an exciting new technology to recombinant protein production and conjugates that identifies the need our customers have for a predictable, stable and efficient supply chain in this growing area.

Targeted therapy delivers micro doses of therapeutic molecules directly to the diseased cells while limiting exposure of healthy cells.
Recombinant DNA technology allows the ease of production of desired proteins in suitable expression systems.